What is Karius?
Karius operates at the intersection of biotechnology and data science, specializing in the development of non-invasive genomic tests that detect a broad spectrum of pathogens from a single blood sample. By utilizing cell-free DNA (cfDNA) sequencing, the company provides a comprehensive diagnostic solution that bypasses the limitations of traditional culture-based methods. This technological edge positions Karius as a leader in the precision medicine landscape, enabling healthcare providers to rapidly identify causative agents in immunocompromised and critically ill patients. The firm's market position is bolstered by its ability to integrate seamlessly into existing clinical workflows, thereby enhancing diagnostic accuracy and optimizing therapeutic outcomes in high-acuity environments.
How much funding has Karius raised?
Karius has raised a total of $320M across 4 funding rounds:
Other Financing Round
$5M
Series A
$50M
Unspecified
$165M
Series C
$100M
Other Financing Round (2014): $5M with participation from Innovation Endeavors, Lightspeed Venture Partners, and Data Collective
Series A (2017): $50M led by Lightspeed Venture Partners, Tencent, Pacific 8 Ventures, Innovation Endeavors, and Data Collective
Unspecified (2020): $165M supported by Khosla Ventures, General Catalyst, HBM Healthcare Investments, LightSpeed Venture Partners, and SoftBank Vision Fund 21
Series C (2024): $100M featuring General Catalyst, Seventure Partners, HBM Healthcare Investments, 5AM Ventures, Khosla Ventures, and Gilde Healthcare
Key Investors in Karius
General Catalyst
General Catalyst is a venture capital firm that supports transformational business opportunities across multiple sectors, leveraging deep operational expertise to help companies scale at critical inflection points.
Lightspeed Venture Partners
Lightspeed Venture Partners is a global multistage firm that invests in early and growth-stage technology companies, partnering with founders from seed through IPO.
HBM Healthcare Investments
HBM Healthcare Investments is a publicly traded firm focused on the global healthcare sector, capitalizing on growth opportunities driven by medical advancements and innovative therapies.
What's next for Karius?
With the successful closure of its latest financing round, Karius is well-positioned to accelerate its commercial footprint and deepen its research and development initiatives. The strategic capital will likely be deployed to scale laboratory operations, expand the clinical utility of its diagnostic platform, and support ongoing efforts to secure broader reimbursement coverage. As the company moves into its next phase of growth, the focus will remain on scaling its infrastructure to meet the increasing demand for rapid, accurate infectious disease diagnostics. Furthermore, the continued support from its diverse investor base provides the necessary operational expertise to navigate the complexities of the global healthcare market, ensuring that Karius remains at the forefront of the molecular diagnostics revolution.
See full Karius company page
